pidotimod
Small moleculeexperimental
Pidotimod is an immunostimulant. — Wikipedia
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
1
Earliest trial started May 31, 2020 (NCT04322669)
Timeline
No events for the selected filters.
Indications
Approved for
Studied for
Mechanism of action
- MAP kinase ERK1INHIBITOR
MAPK3 inhibitor
- Mitogen-activated protein kinase 1INHIBITOR
MAPK1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaPidotimod ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04322669 | Phase 4 | May 31, 2020 | Almirall |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Almirall | For profit | 1 | 1 | 1 | 2020 |
1 organizations
Page 1 / 1